Filing Flows › Cardiff Oncology (CRDF) › Q4 2024
Cardiff Oncology (CRDF) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
Cardiff Oncology (CRDF) reported revenue of $151K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and -8% from the quarter before.
Cardiff Oncology, Q4 2024: revenue $151K (-3% year over year), net loss $11.8M, operating cash flow −$10.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $151K | -8% | -3% |
| Operating profit | −$12.6M | — | — |
| Net earnings | −$11.8M | — | — |
| Operating cash flow | −$10.3M | — | — |
What changed
Revenue was $151K in Q4 2024, down 3% year over year and down 8% from the previous quarter.
Operating costs exceeded revenue by $12.6M, an operating margin of -8325.8%. Total costs grew 21% against a revenue fall of 3%. The fastest-growing cost line was Research & development (+25%). The quarter ended with a net loss of $11.8M, narrower than the previous quarter's $11.9M loss.
Operating cash flow was −$10.3M. Non-cash charges added back $96K of depreciation and amortization and $1.2M of share-based compensation.
Questions
What was Cardiff Oncology's revenue in the fourth quarter 2024?
Cardiff Oncology (CRDF) reported revenue of $151K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and -8% from the quarter before.
Source: Cardiff Oncology 10-K on SEC EDGAR.